Aviva Holdings Ltd. Esperion Therapeutics, Inc. Transaction History

Aviva Holdings Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $863 Million - $1.13 Billion	21,523,855 Added 4873.52%	21,965,504 $105 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $922,530 - $1.23 Million	-23,000 Reduced 4.95%	441,649 $17.7 Million
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $27.2 Million - $43.5 Million	-735,451 Reduced 61.28%	464,649 $21.4 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $37.4 Million - $78.9 Million	1,032,513 Added 616.11%	1,200,100 $47 Million
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $8.01 Million - $9.81 Million	-121,513 Reduced 42.03%	167,587 $12.1 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $12.7 Million - $15.3 Million	289,000 Added 289000.0%	289,100 $0
Q1 2017 Feb 14, 2018	BUY	N/A	100	100 $4,000

214

129M

1.78M

1.27M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $112M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Aviva Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Aviva Holdings Ltd. with notifications on news.